Abiomed Provides Multi-Year Grant to Boston Children's Hospital Heart Center

Abiomed Provides Multi-Year Grant to Boston Children's Hospital Heart Center

DANVERS, Mass., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD),
a leading provider of breakthrough heart support technologies, today reported
its donation of an unrestricted grant in the amount of $375,000 to Boston
Children's Hospital Heart Center, a newly dedicated cardiovascular care center
founded within Boston Children's Hospital.

The Boston Children's Hospital Heart Center integrates all pediatric
specialists related to a patient's care in order to treat both the heart and
the whole child. This organizational structure allows for a more focused
clinical approach and a fully aligned research effort so that new therapies
have the best chance of treating today's patients. Abiomed's funding will help
support research and education initiatives of the Heart Center's Advanced
Cardiac Therapies (ACT) Program.  Among the uses of these funds, the
following scientific and clinical goals will be pursued:

  *Advance the understanding of basic pathophysiology and symptom correlation
    in pediatric acute decompensated heart failure patients.
  *Engage key opinion leaders to assess the potential for multi-center
    registries and improved methodologies for monitoring neurologic function
    and quality of life for pediatric patients who receive mechanical
    circulatory support.
  *Investigate new cellular and genomic cardiac regeneration therapies that
    will stimulate myocardial recovery.

"We are very thankful for Abiomed's generosity in providing this gift to
Boston Children's Hospital Heart Center," said Sandra Fenwick, President and
Chief Executive Officer, Boston Children's Hospital. "Boston Children's is a
leader and innovator in pediatric cardiology and heart surgery. This grant
from Abiomed, supporting our scientific and clinical goals, will help us
advance the care of children with advanced heart failure.

Boston Children's Hospital Heart Center is one of the nation's most active
pediatric heart failure and transplant centers, managing some of the most
complex pediatric and adult congenital heart failure cases in the world and is
consistently ranked number one in Pediatric Cardiology and Heart Surgery by US
News & World Report.

"We are very excited about this area of research for pediatric heart failure
patients. Abiomed is pleased to support Boston Children's research and
advancements for new, cutting edge technologies in the field of pediatric
cardiac care," said Michael R. Minogue, Chairman, President and Chief
Executive Officer of Abiomed.

* The Impella pediatric device is not approved by the FDA


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support. Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com


This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future losses,
complex manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the most recently filed
Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are
cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
that occur after the date of this release or to reflect the occurrence of
unanticipated events.


Boston Children's Hospital is home to the world's largest research enterprise
based at a pediatric medical center, where its discoveries have benefited both
children and adults since 1869. More than 1,100 scientists, including seven
members of the National Academy of Sciences, 13 members of the Institute of
Medicine and 14 members of the Howard Hughes Medical Institute comprise Boston
Children's research community. Founded as a 20-bed hospital for children,
Boston Children's today is a 395 bed comprehensive center for pediatric and
adolescent health care grounded in the values of excellence in patient care
and sensitivity to the complex needs and diversity of children and families.
Boston Children's is also the primary pediatric teaching affiliate of Harvard
Medical School. For more information about research and clinical innovation at
Boston Children's, visit www.bostonchildrens.org.

CONTACT: For further information please contact:
         Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development

         Aimee Genzler
         Corporate Communications Manager

Abiomed Logo
Press spacebar to pause and continue. Press esc to stop.